pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Avidity Biosciences Inc · news · pharmadog
← back to Avidity Biosciences Inc
News mentioning Avidity Biosciences Inc
33
stories
10h
Novartis projects slowed growth, pins hopes on billions in pipeline potential
biospace
21h
9 biotechs will cut at least half their California workforces
biospace
22h
Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustment
fiercebiotech
9d
STAT+: PepGen says early trial for muscular dystrophy drug looks promising
stat
10d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
20d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
22d
Lilly shuffles business structure; Novartis writes off part of Avidity deal
biopharma dive
23d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
23d
After $1.9B impairment hit, Novartis stands by $12B bet on Avidity
endpoints
23d
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
fiercebiotech
Oct 9, 26
How Abogen went from COVID hype to a $7.8B Novartis deal
biospace
Oct 7, 26
STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few
stat
Oct 2, 26
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
Sep 30, 26
Trend of women-led M&A fades in 2026 with just two deals so far
biospace
Sep 17, 26
After Novartis’ devastating M&A losses, long live the executive willing to try
biospace
Sep 17, 26
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
biospace
Sep 16, 26
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
biospace
Sep 11, 26
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
biopharma dive
Sep 11, 26
Frazier adds $1.1B+ to small and mid-sized biotech fund
biospace
Sep 11, 26
Novartis drags peers down with triple asset stumble
biospace
Sep 11, 26
Novartis drags peers down with triple asset failure
biospace
Sep 11, 26
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
Sep 10, 26
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
fiercebiotech
Sep 9, 26
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
biospace
Sep 8, 26
Novartis RNA drug falls short in rare muscle disease study
biopharma dive
Sep 8, 26
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
Sep 8, 26
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
fiercebiotech
Aug 11, 26
Epicrispr raises $90M to rewrite treatment of rare muscle disease
fiercebiotech
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Jul 21, 26
Novartis climbs on upbeat drug sales as key readouts loom
biopharma dive
← prev
page 1 of 2
next →